Compare BSRR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSRR | IMMP |
|---|---|---|
| Founded | 1977 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.7M | 58.2M |
| IPO Year | 2001 | 2012 |
| Metric | BSRR | IMMP |
|---|---|---|
| Price | $35.96 | $0.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $37.00 | $5.50 |
| AVG Volume (30 Days) | 30.7K | ★ 19.6M |
| Earning Date | 04-20-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 10.28 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.74 | $417.85 |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $11.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.06 | $0.29 |
| 52 Week High | $38.60 | $3.53 |
| Indicator | BSRR | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 61.84 | 40.41 |
| Support Level | $32.93 | N/A |
| Resistance Level | $36.75 | $1.75 |
| Average True Range (ATR) | 0.76 | 0.07 |
| MACD | 0.27 | 0.11 |
| Stochastic Oscillator | 80.88 | 43.69 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.